Reports Q3 revenue EUR 1.27M vs. EUR 976.000 last year. “Our actions in the third quarter have further positioned us well for a successful U.S. commercial launch. On the back of the robust DREAM data presented in September, we have raised additional capital and are actively focused on building up our U.S. commercial team,” commented Olivier Taelman, Nyxoah’s (NYXH) Chief Executive Officer. “I am more confident than ever that we have set Genio up for a strong commercial start in the U.S. immediately after FDA approval.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NYXH:
- Nyxoah participates in a conference call with Cantor Fitzgerald
- Nyxoah Strengthens Leadership for U.S. and Global Expansion
- Nyxoah to Announce Q3 2024 Financial Results
- Nyxoah Shareholdings Shift: Hambrecht and BlackRock Update
- Nyxoah price target lowered to $17 from $18 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
